Printer Friendly

-Biotec Pharmacon limits net loss to NOK5.4m in Q3 2011.

M2 EQUITYBITES-November 8, 2011--Biotec Pharmacon limits net loss to NOK5.4m in Q3 2011(C)2011 M2 COMMUNICATIONS

8 November 2011 - Norwegian company Biotec Pharmacon ASA (OSL:BIOTEC) said today its net loss melted to NOK5.4m in the third quarter of 2011 from NOK7.9m a year earlier.

The better result mirrors mainly the completion of the Phase III trials in the first half of the year, the workforce reduction and other downsizing in external research activities in 2011, the firm said.

Biotec Pharmacon's cash position at the end of September was NOK42m.

Third-quarter sales rose to NOK4.9m from NOK2.2m in the previous year. Revenue from the Enzymes segment rose 158% to NOK3.1m.

The operating loss narrowed to NOK5.7m in the third quarter of 2011 from NOK8m in the third quarter of 2010, due to staff reduction.

(EUR1 = NOK7.4)

((Comments on this story may be sent to>PDNovember 8, 2011>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Financial report
Date:Nov 8, 2011
Previous Article:-Banco de Valencia considers capital increase.
Next Article:-Swedish Nibe takes over 10% in US Enertech Global.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters